ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: TH-PO386

Characteristics of the US ESRD Population With Autosomal Dominant Polycystic Kidney Disease

Session Information

Category: Genetic Diseases of the Kidneys

  • 1101 Genetic Diseases of the Kidneys: Cystic


  • Stevanovic, Mirjana, Dartmouth Guarini School of Advanced Studies, Hanover, New Hampshire, United States
  • Graber, Martha L., Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, United States

We present recent data concerning US individuals with autosomal dominant polycystic kidney disease (APCKD) and ESRD


We used data from the US Renal Data System (USRDS) 2014 - 2018 to compare prevalent persons with ESRD and ADPCKD to those without ADPCKD


Persons with ADPCKD (N = 42714) comprised 3.1% of the US ESRD population. APCKD accounted for 99.4 % of all adult cystic disease categories (data not shown).

Persons with ADPCKD were younger on entry to the ESRD program by 4.9 years, more likely to be female and White, to have had nephrology care, to have initiated with peritoneal dialysis or transplant, and to have received a living donor kidney. There was no difference in the risk of death.


The vast majority, 99.4%, of persons with adult cystic diseases on entry to the ESRD program have a diagnosis of APCKD. Those with APCKD comprised 3.1% of the total US ESRD population, a figure consitent with data from the USRDS 1998 annual report, Europe and Japan, but lower than has been commonly reported in the US. We estimate that 3 - 7% of all US persons with APCKD are ion dialysis or have a transplant at any one time.

On entry to the ESRD program individuals with ADPCKD were younger, more likely to be White and female, to have had prior nephrology care, to have initiated renal replacement therapy with peritoneal dialysis or transplant and to have received a living donor graft than those with ESRD without APCKD. There was no significant difference in the risk of death during a five year period.

These findings contribute to our understanding of the epidemiology, risks, and outcomes of APCKD .


  • Other NIH Support